title: Design and in vitro performance evaluation of purified microparticles of pravastatin sodium for intestinal delivery.
abstract: The purpose of research was to develop a mucoadhesive multiparticulate sustained drug delivery system of pravastatin sodium, a highly water-soluble and poorly bioavailable drug, unstable at gastric pH. Mucoadhesive microparticles were formulated using eudragit S100 and ethyl cellulose as mucoadhesive polymers. End-step modification of w/o/o double emulsion solvent diffusion method was attempted to improve the purity of the product, that can affect the dose calculations of sustained release formulations and hence bioavailability. Microparticles formed were discrete, free flowing, and exhibited good mucoadhesive properties. DSC and DRS showed stable character of drug in microparticles and absence of drug polymer interaction. The drug to polymer ratio and surfactant concentration had significant effect on mean particle size, drug release, and entrapment efficiency. Microparticles made with drug: eudragit S100 ratio of 1:3 (F6) exhibited maximum entrapment efficiency of 72.7% and ex vivo mucoadhesion time of 4.15 h. In vitro permeation studies on goat intestinal mucosa demonstrated a flux rate (1,243 μg/cm(2)/h) that was 169 times higher than the flux of pure drug. The gastric instability problem was overcome by formulating the optimized microparticles as enteric-coated capsules that provided a sustained delivery of the highly water-soluble drug for 12 h beyond the gastric region. The release mechanism was identified as fickian diffusion (n = 0.4137) for the optimized formulation F6. Conclusively, a drug delivery system was successfully developed that showed delayed and sustained release up to 12 h and could be potentially useful to overcome poor bioavailability problems associated with pravastatin sodium.
authors: Department of Pharmaceutics, Rajiv Academy for Pharmacy, Mathura, India.
authors: Yogesh
authors: Y
authors: Garg
authors: Kamla
authors: K
authors: Pathak
references: Drug Dev Ind Pharm. 2008 Apr;34(4):349-54
references: 18401776
references: Pharm Dev Technol. 1998 Nov;3(4):597-606
references: 9834964
references: Indian J Physiol Pharmacol. 2008 Apr-Jun;52(2):211-3
references: 19130870
references: Eur J Pharm Biopharm. 2008 Feb;68(2):245-52
references: 17574825
references: AAPS PharmSciTech. 2006 Feb 10;7(1):E12
references: 16584142
references: Int J Pharm. 2004 Mar 1;271(1-2):281-6
references: 15129995
references: Int J Pharm. 2003 Jul 9;260(1):115-21
references: 12818816
references: Chem Pharm Bull (Tokyo). 1997 Sep;45(9):1539-43
references: 9332006
references: Drug Dev Ind Pharm. 2009 Oct;35(10):1155-66
references: 19555239
references: J Microencapsul. 2005 Dec;22(8):863-76
references: 16423758
references: Indian J Pharm Sci. 2008 Jan;70(1):77-84
references: 20390085
references: Int J Pharm. 2008 Mar 3;351(1-2):244-9
references: 18024022
references: Int J Pharm. 2005 Jan 20;288(2):295-303
references: 15620870
references: Int J Pharm. 2000 Feb 25;196(1):75-83
references: 10675709
references: Adv Drug Deliv Rev. 2005 Nov 3;57(11):1556-68
references: 16198441
references: AAPS PharmSciTech. 2010 Mar;11(1):416-24
references: 20300898